Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220

Futu NewsDec 21 02:31 · Ratings

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

BenzingaDec 19 21:42

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194

Futu NewsDec 18 23:31 · Ratings

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211

Futu NewsDec 17 21:00 · Ratings

Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191

BreakingsDec 17 13:11

Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus

TipRanksDec 17 10:05 · Ratings